Journal of Hepatology

Papers
(The H4-Index of Journal of Hepatology is 93. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)
ArticleCitations
A step forward to predict the risk of post-hepatectomy portal hypertension2237
Further on ammonia concentration, -clearance, -removal, and -production1332
Editorial Board993
Let’s unite Hepatology! Become an EASL member today and discover your benefits951
Reply to: “We need to talk about #livertwitter”881
Fritz von Weizsäcker 1960–2019: An exceptional physician-scientist819
Editorial Board664
Reply to: “Reassessing the causal relationship between liver diseases and cardiovascular outcomes” and “From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank”394
Get ready for the EASL Studio season 6!284
Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody283
Viral Hepatitis Elimination 2022 – Don’t miss this special conference in Brussels & register with early fees by 4 January!252
Apply now for the EASL School 2022249
Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease248
From the Editor’s Desk...239
Reply to: “Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis”231
From the Editor’s Desk...219
The protective association of HLA-B∗52:01, HLA-C∗12:02, and DQB1∗06:01 alleles with severe acute hepatitis of unknown origin in Japanese children216
Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms213
The space of Mall confirmed in humans: A response to “Portal venous branches as an anatomic railroad for a gut-bile duct axis”212
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April211
Visit EASL Campus & discover 4,100 + resources on hepatology & liver-related research205
Rising clinical and economic burden among hepatitis D patients who attended Spanish hospitals200
Defining the prognosis of critically ill patients with alcohol-related liver disease200
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis188
Reply to: “TIPS and liver transplantation should always be discussed together”181
Join the EASL Community & enjoy reduced fees to all EASL events178
Transient elastography in chronic liver disease: Beware of the cut-offs!176
Combination of crafity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma173
Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential172
Combination immunotherapy for hepatocellular carcinoma170
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease164
Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis162
Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD161
A pilot study to improve the uptake of hepatocellular carcinoma surveillance159
Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease159
Become an EASL Member & join the global liver community, or renew your membership159
Prevalence and incidence of delta hepatitis in HIV-HBV coinfected patients in the Dat’AIDS cohort157
Estimating the economic value allocation of the social surplus generated by the utilization of second-generation direct-acting antivirals for hepatitis C in the United States, 2015–2019153
SIRIUS project: sensing probe exploring liver fibrosis in Slovakia150
Global burden of common cancers attributable to metabolic risks from 1990 to 2019150
Opt-out testing for hepatitis B and C infections in adults attending the emergency department of a London Hospital149
Late presentation of chronic hepatitis C for care in Georgia: data from the national hepatitis C elimination program, 2016–2021148
The impact of hepatitis D virus infection on health-related quality of life and fatigue in patients untreated for HDV: descriptive results from a cross-sectional study across Italy, Germany, Spain and148
Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers148
Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona144
One step closer to the goal: mobile InfoHep centre offering detection, protection, prevention and treatment/linkage- to care services in Croatian penalty institutions144
Automation of hepatitis C screening through electronic health record algorithm141
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021138
Acceptance and feasibility of hepatitis C screening by assisted self-testing in high-risk and general population: a randomized clinical trial136
FIB-4 outperforms other serum non-invasive fibrosis tests in metabolic associated fatty liver disease134
Glycemic control as a modifiable and independent risk factor for the development of liver, biliary tract and pancreatic cancer: a territory-wide study of 273,421 patients with diabetes mellitus132
Results of the Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study 1.1 on the reproducibility and repeatability of shear-wave and transient elastography in non-alcoholic fatty liver dise130
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm129
Study of hepatitis delta virus replication markers in anti-HBc positive patients with chronic hepatitis C128
Epidemiology and characteristics of hepatocellular carcinoma in France: results of the first 2000 patients in real-life situations from the French prospective chief cohort128
Incidence of hepatitis D virus super-infection in HBsAg positive patients (The Inci-D cohort study)127
Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib127
Significant heterogeneity in long-term risks of cirrhosis or hepatocellular carcinoma among a national cohort of U.S. veterans with non-cirrhotic, treatment naïve chronic hepatitis B in the immune tol125
Bisphosphonate-loaded nanogels attentuate liver fibrosis by repolarization of M2-type macrophages125
Performance of the Steatosis-Associated Fibrosis Estimator (SAFE) to predict F2 fibrosis and higher in a cohort of South Korean patients with non-alcoholic fatty liver disease (NAFLD)124
Experimental fibrosis alters matrix-bound vesicles cargo that do not revert after histologic recovery124
Estimating the residual risk of hepatitis B mother-to-child transmission in The Gambia, 30 years after HBV vaccine implementation124
Fragility index of positive phase 2 and 3 randomized clinical trials of treatment of hepatocellular carcinoma (2002–2022)124
Using qFibrosis analysis to predict disease and survival outcome of patients with hepatocellular carcinoma after curative treatment122
Contrasting immune fingerprints of chronic hepatitis B Virus infection in adults from South Africa and the United Kingdom122
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study121
Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis117
Identification and external validation of the optimal ALT thresholds for ruling in significant histologic disease in chronic hepatitis B114
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study113
Imaging of fibrosis in metabolic associated liver disease by a radiolabeled affibody targeting PDGFRB113
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis108
Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib106
Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling105
Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction105
Risk stratification for early recurrence after resection in patients with intermediate stage hepatocellular carcinoma105
Long-term outcome following liver transplantation for patients with acute on chronic liver failure grade 3 (ACLF-3): a retrospective matched-controlled study104
The protective effect of time-caloric restriction in liver fibrosis induced by nitrosamines in rat model104
Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece104
Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B104
Stability of Hepatitis B virus RNA in plasma and serum under various storage conditions103
Quantitative digital pathology of 3D human NASH models establish continuous scores to evaluate the antifibrotic effects of Selonsertib, Firsocostat and Resmetiron102
Addressing the heterogeneity of fibrosis in liver biopsy specimens with qFibrosis – a new paradigm for an old problem102
Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis100
Sequential systemic treatment in patients with hepatocellular carcinoma: real-world data in the era of immune checkpoint inhibition99
Exploring gender-related differences in liver fibrosis and regeneration through a new experimental carbon tetrachloride protocol in mice99
Epidemiological landscape and clinical spectrum of chronic hepatitis B in East Africa97
Inhibition of tumour progression locus 2 (TPL2) halts the progression of liver fibrosis in a stringent long term choline deficient high-fat diet (CdHFD) rat model96
Multispectral imaging analysis of liver biopsies from patients with non-alcoholic steatohepatitis reveals enrichment of pathogenic macrophage phenotypes associated with disease progression95
Clinical impact of relative dose intensity over the first four weeks in cabozantinib therapy for unresectable hepatocellular carcinoma94
Aspirin use and risk of hepatocellular carcinoma and gastrointestinal bleeding in patients with HBV-related cirrhosis: a landmark analysis94
Diabetes, but not prediabetes, is associated with significant liver fibrosis94
Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis93
Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease93
Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV-uninfected recipients: results from the HCV-TARGET study93
0.23733282089233